Phase 3Completed
Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema
Phase III Non-inferiority Clinical Study to Evaluate the Efficacy and Safety of Intravitreous PRO-169 Compared to Ranibizumab for Diabetic Macular Edema
- Sponsor
- Laboratorios Sophia S.A de C.V. (Industry)
- Enrollment
- 509 enrolled
- Conditions
- Diabetic Macular Edema
- Interventions
- Bevacizumab; Lucentis®
- Ages
- adults, older adults
- Registry
- NCT05217680
Full record on ClinicalTrials.gov
From the registry
Phase III clinical study to evaluate the efficacy, expressed as improvement in visual acuity in patients suffering diabetic macular edema after one year of treatment with PRO-169, compared to treatment with Lucentis® (ranibizumab).
Primary outcomes
- Best Corrected Visual Acuity
History
Last registry update
Results first posted
Study completion
Primary completion
Registered
Started